Overview

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2020-07-14
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Kadmon Corporation, LLC